scholarly journals P3546Result of surgical treatment of obstructive hypertrophic cardiomyopathy with coronary heart disease

2018 ◽  
Vol 39 (suppl_1) ◽  
Author(s):  
Y Meng ◽  
S Wang ◽  
Y Zhang ◽  
Q Yu
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Surgical Treatment ◽  
Hypertrophic Cardiomyopathy ◽  
Obstructive Hypertrophic Cardiomyopathy

scholarly journals Mavacamten Decreases Maximal Force and Ca2+-sensitivity in the N47K-Myosin Regulatory Light Chain Mouse Model of Hypertrophic Cardiomyopathy

2020 ◽  
Author(s):  
Peter O Awinda ◽  
Marissa Watanabe ◽  
Yemeserach M. Bishaw ◽  
Anna M Huckabee ◽  
Keinan B Agonias ◽  
...  
Keyword(s):  
Heart Disease ◽  
Hypertrophic Cardiomyopathy ◽  
Light Chain ◽  
Isometric Force ◽  
Regulatory Light Chain ◽  
Isometric Tension ◽  
Myosin Regulatory Light Chain ◽  
Cardiac Myosin ◽  
Cross Bridge ◽  
Obstructive Hypertrophic Cardiomyopathy

Morbidity and mortality associated with heart disease is a growing threat to the global population and novel therapies are needed. Mavacamten (formerly called MYK-461) is a small molecule that binds to cardiac myosin and inhibits myosin ATPase. Mavacamten is currently in clinical trials for the treatment of obstructive hypertrophic cardiomyopathy (HCM), and it may provide benefits for treating other forms of heart disease. We investigated the effect of mavacamten on cardiac muscle contraction in two transgenic mouse lines expressing the human isoform of cardiac myosin regulatory light chain (RLC) in their hearts. Control mice expressed wild-type RLC (WT-RLC), and HCM mice expressed the N47K RLC mutation. In the absence of mavacamten, skinned papillary muscle strips from WT-RLC mice produced greater isometric force than strips from N47K mice. Adding 0.3 µM mavacamten decreased maximal isometric force and reduced Ca2+-sensitivity of contraction for both genotypes, but this reduction in pCa50 was nearly twice as large for WT-RLC vs. N47K. We also used stochastic length-perturbation analysis to characterize cross-bridge kinetics. The cross-bridge detachment rate was measured as a function of [MgATP] to determine the effect of mavacamten on myosin nucleotide handling rates. Mavacamten increased the MgADP release and MgATP binding rates for both genotypes, thereby contributing to faster cross-bridge detachment, which could speed myocardial relaxation during diastole. Our data suggest that mavacamten reduces isometric tension and Ca2+-sensitivity of contraction via decreased strong cross-bridge binding. Mavacamten may become a useful therapy for patients with heart disease, including some forms of HCM.

What Is the Best Surgical Treatment for Obstructive Hypertrophic Cardiomyopathy and Degenerative Mitral Regurgitation?

2009 ◽  
Vol 88 (3) ◽  
pp. 727-732 ◽  
Author(s):  
Calvin K.N. Wan ◽  
Joseph A. Dearani ◽  
Thoralf M. Sundt ◽  
Steve R. Ommen ◽  
Hartzell V. Schaff
Keyword(s):  
Surgical Treatment ◽  
Hypertrophic Cardiomyopathy ◽  
Mitral Regurgitation ◽  
Obstructive Hypertrophic Cardiomyopathy

scholarly journals Surgical treatment of patients with coronary heart disease and mild stenosis of the aortic valve

2014 ◽  
Vol 2 (1) ◽  
pp. 9-14
Author(s):  
Anatoly Molochkov ◽  
Igor Zhbanov ◽  
Boris Shabalkin ◽  
Vadim Domnin
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Surgical Treatment ◽  
Aortic Valve ◽  
Mild Stenosis

scholarly journals Surgical treatment of a patient with coronary heart disease and post-infarction left ventricular aneurism associated with aortic stenosis

2017 ◽  
Vol 95 (8) ◽  
pp. 758-761
Author(s):  
I. A. Borisov ◽  
Vadim V. Dalinin ◽  
P. E. Krainyukov ◽  
N. O. Travin
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Surgical Treatment ◽  
Aortic Valve ◽  
Aortic Stenosis ◽  
Left Ventricular ◽  
Unique Combination ◽  
Heart Pathology ◽  
Valve Prostheses

The paper reports a case of successful surgical treatment of a patient with coronary heart disease and post-infarction left ventricular aneurism associated with aortic stenosis. The unique combination of these two conditions is discussed along with advantages of seamless aortic valve prostheses for the treatment of combined heart pathology.

scholarly journals Results of the alcohol septal ablation in combination with simultaneous endoprosthesis of coronary arteries in treatment of patients, suffering obstructive hypertrophic cardiomyopathy and concurrent ischemic heart disease

2019 ◽  
Vol 86 (11-12) ◽  
pp. 3-8
Author(s):  
K. V. Rudenko ◽  
L. O. Nevmerzhytska ◽  
O. Yu. Dudnyk ◽  
S. M. Fanta ◽  
V. V. Lazoryshynets
Keyword(s):  
Heart Disease ◽  
Hypertrophic Cardiomyopathy ◽  
Ischemic Heart Disease ◽  
Coronary Arteries ◽  
Systolic Pressure ◽  
Ischemic Heart ◽  
Alcohol Septal Ablation ◽  
Significant Difference ◽  
Obstructive Hypertrophic Cardiomyopathy

Objective. To study the immediate and remote follow-up results of treatment in patients, suffering obstructive hypertrophic cardiomyopathy and concurrent ischemic heart disease, using the alcohol septal ablation in combination with simultaneous endoprosthesis of coronary arteries. Materials and methods. In the investigation were included 129 patients, suffering obstructive hypertrophic cardiomyopathy, to whom the alcohol septal ablation was performed in 2009 - 2018 yrs in M. M. Amosov National Institute of Cardiovascular Surgery. All the patients were distributed into two groups: the first -14 (10.9%) patients with concurrent ischemic heart disease and the second -115 (89.1%) patients without concurrent ischemic heart disease. Results. Reduction of the systolic pressure gradient in the exit tract of the left ventriculus, mitral regurgitation, and the functional class characteristic in accordance to criteria of a New-York Association of Cardiologists in both groups in immediate and late periods of observation have appeared statistically proved. In a remote period of follow-up in 13 (92.9%) patients, suffering the ischemic heart disease, a satisfactory hemodynamical result was registered, and in 1 (7.1%) - poor. Conditionally poor results in this group of patients were absent. The patients without an ischemic heart disease (n=107) in accordance to the above mentioned indices were distributed in a follow manner: 74 (69.2%), 28 (26.2%) and 5 (4.7%), accordingly. Statistically significant difference in accordance to hemodynamical results between two groups of patients was absent in immediate and remote periods of follow-up. Conclusion. Simultaneous conduction of the alcohol septal ablation in combination with endoprosthesis of coronary arteries in patients, suffering obstructive hypertrophic cardiomyopathy and concurrent ischemic heart disease, constitutes a safe proved combined intervention procedure, which owes good immediate results, persisting in the remote period.

LOW INVASIVE CORONARY SURGERY: OVERVIEW OF CORONARY HEART DISEASE MODERN SURGICAL TREATMENT TECHNIQUES

2021 ◽  
Vol 16 (3) ◽  
pp. 84-88
Author(s):  
R.V. Sidorov ◽  
A.V. Bazilevich ◽  
A.A. Katkov ◽  
G.G. Borshchev ◽  
V.A. Sorokina ◽  
...  
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Surgical Treatment ◽  
Coronary Surgery ◽  
Treatment Techniques
Sign in / Sign up

Export Citation Format

Share Document